Long-acting Injectable Formulations
Maximising Patient Engagement in Clinical Trials
Complex Journey from Innovation to Patient impact
Two Acts, One Geopolitical Moment
Beyond Reporting - Safety surveillance analytics for medical devices...
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Knowledge Gain Through High Parallel Bioprocess Setups
Product Life Cycle Manager, Eppendorf AG
Sebastian Kleebank studied Bioengineering at the University of Applied Sciences in Juelich followed by his PhD at the RWTH Aachen Institute for Molecular Biotechnology In his actual position as a Product Life Cycle Manager at Eppendorf AG Business Unit Bioprocess he is responsible for the smallscale product portfolio During his years in the bioprocess industry he gained a lot of experience in sma...
Articles
Blockchain for Data Integrity in Biopharma
Data integrity in the Biopharmaceutical industry is a key requirement for maintaining public trust in patient safety and product quality while supporting regulatory compliance It provides assurance that data generated during the entire lifecycle of a pharmaceutical product are complete accurate reliable and compliant with regulations
Research Insights
Real-World Evidence Revelations: The Potential of Patient Support Programmes to Provide Data on Medication Usage
PSPs are not designed to investigate a scientific hypothesis nor typically are they governed by a protocol hence these programmes are not safetyoriented However by their nature these programmes generate potentially
Case Studies
Local Production Of Pharmaceuticals And Related Technology Transfer In Developing Countries
Abstract As stakeholders in the Global Strategy and Plan of Action on Public Health Innovation and Intellectual Property GSPAPHI adopted by the World Health Assembly in the United Nations Conference on Trade and Development UNCTAD the World Health Organization WHO and the International Centre for Trade and Sustainable Development ICTSD are col
Techno Trends
Roche Introduced Inavolisib for the Treatment of HER2-negative Breast Cancer
Roche has introduced inavolisib an oral investigational therapy combined with palbociclib and fulvestrant for treating adult patients with PIKCAmutated hormone receptorpositive HERnegative
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
When Orphan Drugs Make All the Difference
Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.
Tobacco-style Label Warning on Alcohol Products
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry
Chemistry & AI
Dr. Ashok Kumar FRSC, President of the Centre for Research & Development at Ipca, earned his PhD from CDRI with Dr. Nityanand and post-doctoral experience from Sussex University with Nobel Laureate Prof. Cornforth. His interests include Chemical, Biotechnological & NDDR research and also integrating spirituality, philosophy, and common sense in his professional and personal life.
Nanotechnology Strategies for Age –Related Macular Degeneration
Aira Sarkar is pursuing B. Tech (Pharmaceutical Chemistry and Technology) in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Sathish Dyawanapelly is working as an Assistant Professor in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Innovative Approaches for Safer and More Effective Healthcare
Dani is a content strategist passionate about crafting compelling narratives. With a knack for blending creativity and data-driven insights, she specialises in developing content that engages and converts.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
